Lilly Sues Six Firms Over Black-Market Sales of Unapproved Obesity Drug Retatrutide
LLY sits 94% above its 52-week low of $625.9.
Summary
Eli Lilly has filed six lawsuits against US sellers of black-market retatrutide, its experimental obesity drug currently in Phase 3 trials with no regulatory approval. The legal action targets companies allegedly selling unapproved versions, as a black market has emerged, prompting Lilly to refer over 200 entities to authorities. U.S. Customs seizures of illicit GLP-1 drugs surged in July, with nearly 90,000 vials intercepted, underscoring the scale of unauthorized sales. Lilly is also calling on online platforms, payment companies, and regulators to shut down the illegal retatrutide black market. This offensive aims to safeguard a key pipeline asset that recently delivered up to 28% weight loss in trials, reinforcing Lilly's dominance in the obesity market and signaling zero tolerance for IP infringement ahead of potential FDA submission.
At the time of this announcement, LLY was trading at $1,215.20 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $625.90 to $1,249.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.